Wall Street brokerages expect Assembly Biosciences Inc (NASDAQ:ASMB) to post earnings of ($0.91) per share for the current quarter, according to Zacks. Four analysts have issued estimates for Assembly Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.99) and the highest estimate coming in at ($0.77). Assembly Biosciences reported earnings per share of ($0.16) in the same quarter last year, which suggests a negative year-over-year growth rate of 468.8%. The business is scheduled to report its next quarterly earnings results on Thursday, March 14th.
On average, analysts expect that Assembly Biosciences will report full year earnings of ($4.00) per share for the current financial year, with EPS estimates ranging from ($4.51) to ($3.75). For the next fiscal year, analysts expect that the company will post earnings of ($4.19) per share, with EPS estimates ranging from ($5.35) to ($3.02). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Assembly Biosciences.
Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.01) by $0.14. The business had revenue of $4.29 million during the quarter, compared to the consensus estimate of $3.21 million. Assembly Biosciences had a negative net margin of 469.91% and a negative return on equity of 50.63%.
NASDAQ ASMB opened at $22.00 on Thursday. The firm has a market cap of $606.28 million, a P/E ratio of -9.13 and a beta of 1.42. Assembly Biosciences has a 1 year low of $18.58 and a 1 year high of $67.36.
Large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc raised its stake in Assembly Biosciences by 23.0% during the 3rd quarter. Legal & General Group Plc now owns 3,289 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 616 shares during the last quarter. MetLife Investment Advisors LLC acquired a new position in Assembly Biosciences during the 2nd quarter valued at $282,000. Point72 Asset Management L.P. acquired a new position in Assembly Biosciences during the 3rd quarter valued at $407,000. American International Group Inc. raised its stake in Assembly Biosciences by 26.1% during the 3rd quarter. American International Group Inc. now owns 13,946 shares of the biopharmaceutical company’s stock valued at $518,000 after purchasing an additional 2,886 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky acquired a new position in Assembly Biosciences during the 3rd quarter valued at $540,000. Hedge funds and other institutional investors own 84.94% of the company’s stock.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.